A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

Recruiting now. Registry record last updated May 14, 2026.

Who can join: Adults 18+, have obesity, BMI 40+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor Marlene StarrDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 50

What this study is for

Primary condition: Obesity and Obesity-related Medical Conditions. Also studied in: Bariatric Surgery.

Full scientific study title: 2024 Tirzepatide-Bariatric Surgery.

Who can join

Age18 and upSexAnyBMI40 or higher

Adults 18+, have obesity, BMI 40+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

adults who have been enrolled in the multidisciplinary metabolic and bariatric surgery program at the UK HealthCare Weight Loss Surgery Clinic and are scheduled to receive laparoscopic or robotic sleeve gastrectomy, or gastric bypass surgery
BMI greater than or equal to 40 kg/m2 with one or more obesity-related comorbidities
have demonstrated abstinence from any form of nicotine use, confirmed by serum nicotine and metabolite testing
enrollment in the ADORE Bariatric Tissue Bank (IRB #69767)

Key exclusion criteria

any contraindication to the use of tirzepatide (per package insert)
Personal or family history of medullary thyroid carcinoma
Patients with Multiple Endocrine Neoplasm syndrome type 2
Hypersensitivity to tirzepatide
History of pancreatitis

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Kentucky1 site

University of Kentucky
Lexington, Kentucky

Follow this trial

We email you if NCT06721507 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: March 27, 2025. Expected completion: December 31, 2026. Last updated on ClinicalTrials.gov: May 14, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.